Start-ups: „Deutschland hat kein Kapital-, sondern ein Gründerproblem“
Philipp Baaske hat sein Biotechunternehmen ohne Wagniskapital aufgebaut – und schon nach zwei Jahren Profit gemacht. Dass es Gründern an Kapital mangelt, hält er für vorgeschoben.
Düsseldorf - Philipp Baaske, a man with long hair, sits in his new office at the Ludwig-Maximilians-University Munich, having recently left his position as CEO of his Biotech startup, Nanotemper. Nanotemper develops biophysically-based measurement devices for basic research, biotechnology, and the pharmaceutical industry.
In May 2025, Baaske received an unexpected call from the President of LMU. He was invited to become the Vice President for Entrepreneurship, a role that would involve streamlining bureaucracy to enable more spin-offs. Baaske admits this was a high-risk move, with others warning him that the bureaucracy at LMU would be vastly different from the startup world, and that he might fail.
However, Baaske has never been afraid of anything related to money. Consequently, he resigned from his position at Nanotemper, now serving as a shareholder and "Executive Chairman" with a different goal in mind.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Start-ups: "Germany has no capital problem, but a founder problem" handelsblatt.com
